Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full BodyGlobeNewsWire • 10/08/26
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell CarcinomaGlobeNewsWire • 09/14/26
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue GrowthGlobeNewsWire • 08/13/26
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026GlobeNewsWire • 08/05/26
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026GlobeNewsWire • 05/21/26
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic KeratosisGlobeNewsWire • 05/13/26
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/19/26
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026GlobeNewsWire • 03/09/26
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne VulgarisGlobeNewsWire • 03/09/26
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be UnpatentableGlobeNewsWire • 02/26/26
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and ExtremitiesGlobeNewsWire • 02/17/26
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell CarcinomaGlobeNewsWire • 02/11/26
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary EndpointGlobeNewsWire • 02/09/26
Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 02/05/26
Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/05/26
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year GrowthGlobeNewsWire • 01/13/26
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory MilestonesGlobeNewsWire • 01/08/26
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property PortfolioGlobeNewsWire • 12/18/25